|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ALCOHOL MAY CAUSE ORTHOSTATIC HYPOTENSION WHEN CONCURRENTLY USED
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
ERGOTAMINE BIO-AVAILABILITY IS INCREASED
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
MAY POTENTIATE HYPOTENSIVE EFFECTS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
INCREASED RISK OF DEVELOPING METHEMOGLOBINEMIA
|